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General and Biennial meetings and forums from 2004 to 2014 
inclusive. Abstracts were individually reviewed and only 
those with the radiation therapist being the main focus of the 
abstract were selected. The abstracts were then categorized 
according to specific themes based on subject matter. 
Results: In total 14935 abstracts were reviewed and only 46 
(0.3%) had the radiation therapist as the main focus. The 
number of selected abstracts by year ranged from a low of 1 
in 2004 to a high of 24 in 2014, with those from 2013 and 
2014 combined representing 65% of all selected abstracts. 
The selected abstracts were classified into the following 
themes: education (21 of 46), clinical applications (12 of 46), 
role definition (8 of 46), workplace wellness (3 of 46), and 
quality of care (2 of 46). 
Conclusions: Although the roles and responsibilities of 
radiation therapists are expanding and therapists are being 
recognized for their knowledge and skills in radiation 
oncology and cancer care more broadly, our results suggest 
that this expansion has not been proportionally represented 
in the radiation oncology literature as only 0.3% of published 
abstracts had a main focus on the radiation therapist. 
Encouragingly, however, the number of abstracts has 
increased substantially during the past 10 years, with the last 
two years alone far exceeding the preceding years combined. 
As the profession of the radiation therapist evolves and offers 
more opportunities for advanced practice qualifications and 
graduate level education it is expected that research on 
radiation therapists will increase, and the themes of said 
research will become more diverse. 
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Purpose/Objective: SBRT is the standard of care for 
inoperable patients with early-stage lung cancer without 
lymph node involvement. Excellent local control rates have 
been reported in a large number of series. However, 
prescription doses and calculation algorithms vary to a great 
extent between studies, even if most teams prescribe on the 
D95 of the PTV. Type A algorithms are known to produce 
dosimetric discrepancies in heterogeneous tissues such as 
lungs. This study was performed to present a MC prescription 
dose for NSCLC adapted to lesion size and location and 
compare the clinical outcome of two cohorts of patients 
treated with a type A algorithm and standard prescription 
dose or the proposed MC protocols. 
Materials and Methods: All inoperable patients treated in our 
institution between August 2007 and April 2013 with SBRT for 
early-stage lung cancer were included. Treatment planning 
was performed with a type A algorithm (Ray Tracing, RT) 
with 3 fractions of 20 Gy for peripheral lesions and 60 Gy in 5 
fractions for central lesions prescribed to the PTV D95 until 
January 2011. A type B algorithm (Monte Carlo, MC) with 54 
Gy in 3 fractions for peripheral lesions with a diameter under 
30 mm, 60 Gy in 3 fractions for lesions with a diameter over 
30 mm and 55 Gy in 5 fractions for central lesions was used 
for patients treated after this date. All treatment plans were 
recalculated with both algorithms for this study. Spearman’s 
rank correlation coefficient was calculated for GTV and PTV. 
Local control, overall survival and toxicity were compared 
between the two groups  
Results: 205 patients with 214 lesions were included in the 
study. 121 lesions were treated with RT and 93 with MC. D50 
of the GTV calculated with MC was poorly correlated with the 
D95 of the PTV calculated with RT (r=0.116) for lesions with a 
diameter of 20 mm or less. For lesions larger than 20 mm, 
spearman correlation was higher (r=0.618), but still 
insufficient. Overall survival rates were 94% and 86% at one 
and two years respectively. Local control rates were 93% and 
79% at one and two years respectively. There was no 
significant difference between the two groups for overall 
survival (p=0.785) or local control (p=0.934). 56 patients 
(27%) presented a grade 1 lung fibrosis without clinical 
consequences. GTV size was a prognostic factor for overall 
survival (HR=1.026, IC95% [1.01-1.041], p<0.001) and total 
dose was a prognostic factor for local control (HR=0.924, 
IC95% [0.870-0.982], p=0.011). 
Conclusions: The dose calculated with a type A algorithm 
does not correctly reflect the dose actually received by the 
tumor. A type B algorithm should be preferred to directly 
prescribe on the GTV in order to avoid the dose calculation 
variability created by normal lung tissue found in the GTV to 
PTV margin. Patients treated with the proposed protocol had 
the same local control and overall survival rates as patients 
treated with the type A algorithm. 
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Purpose/Objective: We evaluated sequential magnetic 
resonance imagings to assess the inherent response of 
intracranial meningiomas after three-dimensional conformal 
radiation therapy. 
Materials and Methods 
Quantitative tumor volume measurements were generated 
from 126 magnetic resonance images of a total of 26 
patients. Both parametric and nonparametric regression 
analyses were used to assess the relationships of the 
percentage of tumor volume reduction with the elapsed time 
after irradiation and the pattern of tumor volume reduction. 
Results: The median follow-up time was 103.5 months 
(range, 29.6–137.3 months). The mean pre-radiation therapy 
tumor volume was 28.60 cm3 (range, 1.34–167.35 cm3). 
Tumor volume reduction was observed in 96.2% of the study 
population. The mean absolute and relative tumor volume 
reduction were 13.9 cm3 (range, 0.4–84.5 cm3) and 44.6% 
(range, 14.7–89.0%), respectively. After irradiation, the 
tumor volume reduction rate was 8.02% per year. 
Meningiomas that were ≥40 cm3 showed a higher rate of 
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tumor volume reduction than meningiomas that were 3 (8.94% 
vs. 7.59% per year). These results suggest that a notable 
tumor volume reduction is predicted within 3 to 4 years after 
irradiation, and thereafter, the tumor volume decreases at a 
slower rate for more than 10 years. 
Conclusions: The quantitative volumetric analysis of the 
pattern of tumor volume reduction in response to irradiation 
gives an insight into the radiobiological nature of intracranial 
meningiomas after conventionally fractionated radiation 
therapy. 
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Purpose/Objective: To evaluate the safety and efficacy of 
postoperative hyperfractionated concomitant boost proton 
radiotherapy for supratentorial glioblastoma multiforme 
(GBM). 
Materials and Methods: Forty-six patients with supratentorial 
GBM were treated by high dose (96.6 GyE) photon and proton 
radiotherapy. There were 24 males and 22 females, and the 
median age was 58 years old (range: 24 - 76). The KPS were 
50, 60, 70, 80, 90, and 100 % in 1,4,10,12,11, and 8 patients, 
respectively. The median MIB-1 index was 30.8 (range:5.1-
70). The gross total resection, subtotal resection, and partial 
resection were performed for 2, 29, and 15 patients, 
respectively. Photon beam were delivered to the T(2)-
weighted high area on magnetic resonance imaging (MRI) in 
the morning (50.4 Gy in 28 fractions). More than 6 hours 
later, proton beams were delivered to the enhanced area 
plus a 10-mm margin in the first half of the protocol (23.1 
GyE in 14 fractions) and to the enhanced volume in the latter 
half (23.1 GyE in 14 fraction). Concurrent chemotherapy with 
nimustine hydrochloride (80 mg/m2) during first and fourth 
weeks or daily temozolomide (75mg/m2) was administrated 
in 23 and 23 patients, respectively. 
Results: The overall survival rates after 1 and 2 years were 
80.4% and 44.6%, respectively. The median survival period 
was 21.1 months (95% CI: 13.0-29.1). The 1- and 2-year 
progression-free survival rates were 34.8% and 8.7%, 
respectively. There was no significant survival difference 
between nimustine hydrochloride and temozolomide groups 
(p=0.33). Acute toxicity was mainly hematologic and was 
controllable. Late radiation necrosis and 
leukoencephalopathy were seen in 11 and 2 patients, 
respectively, but all patients with radiation necrosis were 
controlled by necrotomy and medical therapy including 
bevacizumab administration. 
Conclusions: Hyperfractionated concomitant boost proton 
radiotherapy (96.6 GyE in 56 fractions) with nimustine 
hydrochloride or temozolomide for GBM was tolerable and 
beneficial for patients with supratentorial GBM. 
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Purpose/Objective: Bevacizumab has been extensively 
studied in recurrent high-grade glioma patients as first and 
second-line therapy. To date, there is a limited number of 
reports on its epidemiological use in an unselected patient 
cohort. Therefore, we report on our experience on a large 
number of patients treated at our institution. 
Materials and Methods: After receiving standard 
radiotherapy (with or without TMZ) patients with recurrent 
malignant glioma were treated with bevacizumab (10mg/kg 
intravenously, q2w), either as mono/combination therapy 
(27.2%), upfront (12%) or in combination to re-irradiation, 
with (22.4%) or without maintenance therapy (38.4%). Median 
prescribed radiation dose during re-treatment was 36Gy, 
conventionally fractionated. 
Results: 125 patients were included in this retrospective 
analysis with proven high-grade glioma. Median age was 50 
years and median KPS at re-treatment 80. Median number of 
bevacizumab cycles preceding progression was three, with 
median four cumulative cycles. 
Median follow-up after initiation of bevacizumab treatment 
was 37 months and median overall survival since first 
diagnosis 29 months (WHO grades III + IV). Median post-
recurrence survival was 9 months, median post-recurrence 
PFS 5 months (PFS-6 36.5%). 
Univariate testing revealed that sex, WHO grade, time 
interval from initial diagnosis, MGMT methylation, IDH 
mutation, combination with irinotecan and age had no 
significant influence on neither PRS nor PR-PFS. Significant 
factors according to PRS/PR-PFS were a KPS < 70 (PR-PFS 
median 3 vs. 6 months, p=0.02; PRS median 5 vs. 10 months, 
p=0.007), a larger number of bevacizumab cycles and the 
respective treatment group (most favorable: re-RT + 
bevacizumab + maintenance therapy). 
Conclusions: Bevacizumab appears to be a valuable agent in 
recurrent malignant glioma therapy. Activity of monotherapy 
was seen, especially in combination with reirradiation. KPS 
was the most important predictor for both PRS and PR-PFS. 
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Purpose/Objective: Glioblastoma (GBM) is a very aggressive 
and radioresistant tumor associated with bad prognosis. 
Current trends in GBM treatments are based on a 
